Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer

BACKGROUND: Circulating tumour cells (CTCs) are mediators of cancer dissemination and the formation of metastasis, which is the leading cause of cancer-related deaths. Experimental models derived from CTCs contribute to understanding the biology of CTCs, their role in dissemination, and the discovery of potential drugs targeting CTCs. METHODS: A xenograft was derived from CTCs isolated from a patient diagnosed with metastatic invasive ductal carcinoma of the breast. The characterisation of the CTCs-derived xenograft (CDX) was conducted through in vivo experimental metastatic assays, RNA-Seq, spectral flow cytometry, and drug sensitivity tests. RESULTS: breast cancer stem cells was confirmed. An RNA-Seq-based comparison of CDX with the primary tumour from the same patient unravelled substantial changes in genes related to cell growth, metabolism, and extracellular signalling. CDX and in vitro cell culture showed sensitivity to carboplatin. A partial response was also observed for vandetanib, which was selected through in silico analysis of transcriptomic data. CONCLUSIONS: We present and characterise a novel model derived from CTCs for understanding the plasticity and behaviour of CTCs and advanced breast cancer. CDX_IBP_01 was established from the CTC-enriched fraction obtained from the patient with progressing breast cancer. Once stably re-transplanted and growing in vivo, the transcriptomes of CDX and archived primary BCa1 samples were compared. 2D and 3D in vitro cell cultures were established from sorted human cancer cells from an in vivo xenograft. Phenotypes of established models and their stability were characterised using spectral flow cytometry. The metastatic potential of CDX was evaluated in an in vivo assay. Finally, the applicability of the established model for in vivo and in vitro drug screening was evaluated. Created in https://BioRender.com .